A study appearing in the April 13 issue of Molecular Cell describes how U of T and Johns Hopkins University researchers designed a device to test for proteins that play an important role in human health and disease. The technology, iMYTH (or integrated membrane yeast-two hybrid system), scans cells to detect proteins that interact with key proteins called ATP-binding cassette (ABC) transporters ?proteins that, when impaired, can cause disease. One of the best known ABC transporters is the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which, when disabled by mutation, causes cystic fibrosis, a hereditary disease that results in progressive disability and early death. Another important ABC protein is the Multidrug Resistance Protein (MRP), which normally removes drug metabolites and toxins from cells in our bodies but when overzealous can contribute to the drug resistance of tumours, thereby thwarting chemotherapy. __IMAGE_2
"All the cells in our bodies contain transporters that are poised in cellular membranes and act as ‘gatekeepers?to allow the entry of certain substances, like nutrients, into the cell and promote the export of other substances, like toxins, out of the cell," says Professor Igor Stagljar, Department of Medical Genetics and Department of Biochemistry at the University of Toronto and lead author of the study. "When the function of these transporters is impaired, disease can result. This device gives us insights as to what proteins are interfering with this process."
iMYTH works by scanning cells to reveal proteins that fit with the transporters, the only screening system sophisticated enough to work with delicate membrane proteins. Simply, if two proteins interact in iMYTH, they will stain the yeast cell bl
'"/>
Source:University of Toronto